跳至主要内容
临床试验/NCT00191906
NCT00191906已完成4 期

A Randomized, Double-Blind, Crossover Comparison of Atomoxetine and Placebo in Child Outpatients With Attention-Deficit/Hyperactivity Disorder, Reading Disorder, or Comorbid Attention-Deficit/Hyperactivity Disorder and Reading Disorder.

Eli Lilly and Company1 个研究点 分布在 1 个国家目标入组 121 人开始时间: 2005年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
121
试验地点
1
主要终点
Stop Signal Reaction Time (SSRT) as Derived From the Stop Signal Reaction Time Paradigm

研究概览

简要总结

To test the hypothesis that a 4 week treatment with atomoxetine is more effective than placebo in patients with combined type Attention Deficit/Hyperactivity Disorder (ADHD), patients with only Reading Disorder, and patients with combined type ADHD and Reading Disorder.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
8 Years 至 12 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Clinical diagnosis with Attention Deficit Hyperactivity Disorder and/or Reading Disorder

排除标准

  • Patients with Conduct Disorder
  • Patients who have a history of Bipolar I or II Disorder, psychosis, or Pervasive Development Disorder.
  • Patients who have a current diagnosis of Vocal Tic Disorder, Obsessive Compulsive Disorder, Major Depressive Disorder, Post Traumatic Stress Disorder, Anxiety Disorder, and certain other learning disorders.

研究组 & 干预措施

Atomoxetine first, then Placebo

Experimental

Atomoxetine, 1.2 mg/kg/day, by mouth (PO) for 4 weeks, 2 week washout period and cross-over to placebo, every day (QD), PO for 4 weeks

干预措施: Atomoxetine Hydrochloride (Drug)

Atomoxetine first, then Placebo

Experimental

Atomoxetine, 1.2 mg/kg/day, by mouth (PO) for 4 weeks, 2 week washout period and cross-over to placebo, every day (QD), PO for 4 weeks

干预措施: placebo (Drug)

Placebo first, then Atomoxetine

Experimental

Placebo, every day (QD), by mouth (PO) for 4 weeks, 2 week washout period and cross-over to atomoxetine 1.2 mg/kg/day, PO for 4 weeks

干预措施: Atomoxetine Hydrochloride (Drug)

Placebo first, then Atomoxetine

Experimental

Placebo, every day (QD), by mouth (PO) for 4 weeks, 2 week washout period and cross-over to atomoxetine 1.2 mg/kg/day, PO for 4 weeks

干预措施: placebo (Drug)

结局指标

主要结局

Stop Signal Reaction Time (SSRT) as Derived From the Stop Signal Reaction Time Paradigm

时间窗: Baseline and Week 4 of initial therapy and Week 4 of crossover therapy

SSRT measures response execution (go trials) and response inhibition (stop trials). Go trials consist of stimulus (airplane). Child to press response button corresponding to direction airplane is pointing. Stop trials consist of go trial and audible stop signal. Initial delay between go trial and stop signal = 250 msec. If child succeeded in inhibiting response, delay on next stop trial increased by 50 msec, otherwise, delay decreased by 50 msec. SSRT = subtract mean delay from mean go signal reaction time. Lower scores mean better ability to suppress response when presented with stop signal.

次要结局

  • Change From Baseline in Mean Stop Signal Reaction Time Comparison of ADHD-C to Normal Control Group in >=10 Year Old Subset(Baseline and 4 weeks of therapy)
  • Change From Baseline in Mean Stop Signal Reaction Time Comparison of ADHD-C+RD and RD to Reading Disordered Control Group in >=10 Year Old Subset(Baseline and 4 weeks of therapy)
  • Lexical Decision Task Mean Reaction Time: Correct Words(Baseline and Week 4 of initial therapy and Week 4 of crossover therapy)
  • Lexical Decision Task Mean Reaction Time: Pseudo Words(Baseline and Week 4 of initial therapy and Week 4 of crossover therapy)
  • Working Memory by Corsi Block Tapping Test (CBTT)(Baseline and Week 4 of initial therapy and Week 4 of crossover therapy)
  • Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored - Total Score(Baseline and Week 4 of initial therapy and Week 4 of crossover therapy)
  • Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored - Inattention Subscale(Baseline and Week 4 of initial therapy and Week 4 of crossover therapy)
  • Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored - Hyperactivity-Impulsivity Subscale(Baseline and Week 4 of initial therapy and Week 4 of crossover therapy)
  • Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored - Total T-Score(Baseline and Week 4 of initial therapy and Week 4 of crossover therapy)
  • Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Improvement Scale(4 week therapy endpoint)
  • Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Severity Scale(4 week therapy endpoint)
  • Change From Baseline in Phonological Task Mean Reaction Time Comparison of ADHD-C to Normal Control Group in >=10 Year Old Subset: Pseudohomophones(Baseline and 4 weeks of therapy)
  • Change From Baseline in Phonological Task Mean Reaction Time Comparison of ADHD-C to Normal Control Group in >=10 Year Old Subset: Pseudo Words(Baseline and 4 weeks of therapy)
  • Change From Baseline in Phonological Task Mean Reaction Time Comparison of ADHD-C+RD and RD to Reading Disordered Control Group in >=10 Year Old Subset: Pseudohomophones(Baseline and 4 weeks of therapy)
  • Change From Baseline in Phonological Task Mean Reaction Time Comparison of ADHD-C+RD and RD to Reading Disordered Control Group in >=10 Year Old Subset: Pseudo Words(Baseline and 4 weeks of therapy)

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验

Comparison of Atomoxetine and Placebo in Children... | 临床试验